NuVasive says it ousted 16-year CEO Alex Lukianov over violations of its expense and personnel policies, leading analysts to speculate that an acquisition is now more likely for the spinal implant maker.
UPDATED April 1, 2015, with analysts' comments, share performance.
Delcath Systems has axed its general counsel as part of ongoing restructuring and to focus more resources on clinical development. The company's 2014 results show improved net losses, largely due to cost-cutting.
Delcath (NSDQ:DCTH) said it axed its general counsel as part of ongoing restructuring, aiming to focus more financial resources on clinical development programs.